Please assess the completion status of the following clinical trial:

Trial Title: Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 80 years~* Lipoprotein (a) \> 150 nmol/L~* Evidence of atherosclerotic cardiovascular disease~Exclusion Criteria:~* Severe renal dysfunction~* History or clinical evidence of hepatic dysfunction~* Malignancy within the last 5 years~* Currently receiving, or less than 3 months at Day 1 since receiving \> 200 mg/day Niacin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 Olpasiran Dose 1 (Type: ACTIVE_COMPARATOR): None
- Arm 2 Olpasiran Dose 2 (Type: ACTIVE_COMPARATOR): None
- Arm 3 Olpasiran Dose 3 (Type: ACTIVE_COMPARATOR): None
- Arm 4 Olpasiran Dose 4 (Type: ACTIVE_COMPARATOR): None
- Arm 5 Placebo Dose 5 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).